2018
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)
Brahmer JR, Govindan R, Anders RA, Antonia SJ, Sagorsky S, Davies MJ, Dubinett SM, Ferris A, Gandhi L, Garon EB, Hellmann MD, Hirsch FR, Malik S, Neal JW, Papadimitrakopoulou VA, Rimm DL, Schwartz LH, Sepesi B, Yeap BY, Rizvi NA, Herbst RS. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). Journal For ImmunoTherapy Of Cancer 2018, 6: 75. PMID: 30012210, PMCID: PMC6048854, DOI: 10.1186/s40425-018-0382-2.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, ImmunologicalCarcinoma, Non-Small-Cell LungConsensusHumansImmunotherapyLung NeoplasmsSocieties, MedicalConceptsNon-small cell lung cancerImmune checkpoint inhibitorsCell lung cancerCheckpoint inhibitorsLung cancerDurable responsesConsensus statementStage III non-small cell lung cancerAdvanced non-small cell lung cancerCancer consensus statementSequencing of therapySecond-line settingAppropriate patient selectionOnly treatment optionAdverse event managementCancer-related mortalityImmunotherapy of cancerEvidence-based recommendationsNew treatment approachesStrength of evidenceAdvanced diseasePatient selectionTargetable mutationsTreatment optionsCancer immunotherapy
2015
Electronic Nicotine Delivery Systems: A Policy Statement From the American Association for Cancer Research and the American Society of Clinical Oncology
Brandon TH, Goniewicz ML, Hanna NH, Hatsukami DK, Herbst RS, Hobin JA, Ostroff JS, Shields PG, Toll BA, Tyne CA, Viswanath K, Warren GW. Electronic Nicotine Delivery Systems: A Policy Statement From the American Association for Cancer Research and the American Society of Clinical Oncology. Journal Of Clinical Oncology 2015, 33: 952-963. PMID: 25572671, DOI: 10.1200/jco.2014.59.4465.Peer-Reviewed Original ResearchConceptsElectronic nicotine delivery systemsClinical OncologyTobacco useAmerican SocietyCancer researchHarm-reduction devicesNumber one preventable causeAmerican AssociationJoint writing groupCombustible tobacco productsClinical cancer researchNicotine delivery systemsCombustible tobacco useAdverse health effectsChildproof capsFormer smokersCigarette smokingPreventable causeTobacco cessationSmoking ratesUS FoodDrug AdministrationENDS useDefinitive dataElectronic cigarettes
2014
American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes
Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, Garrett-Mayer E, Herbst RS, Lilenbaum RC, Sima C, Venook AP, Gonen M, Schilsky RL, Meropol NJ, Schnipper LE. American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes. Journal Of Clinical Oncology 2014, 32: 1277-1280. PMID: 24638016, DOI: 10.1200/jco.2013.53.8009.Peer-Reviewed Original Research
2013
Addressing Tobacco Use in Patients With Cancer: A Survey of American Society of Clinical Oncology Members
Warren GW, Marshall JR, Cummings KM, Toll BA, Gritz ER, Hutson A, Dibaj S, Herbst R, Mulshine JL, Hanna N, Dresler CA. Addressing Tobacco Use in Patients With Cancer: A Survey of American Society of Clinical Oncology Members. JCO Oncology Practice 2013, 9: 258-262. PMID: 23943904, PMCID: PMC3770508, DOI: 10.1200/jop.2013.001025.Peer-Reviewed Original ResearchMeSH KeywordsData CollectionHumansMedical OncologyNeoplasmsPractice Patterns, Physicians'Smoking CessationSocieties, MedicalTobacco UseConceptsCessation supportTobacco usePractice patternsASCO membersInitial visitCessation interventionsTobacco assessmentTobacco cessation supportTobacco cessation interventionsAmerican SocietyClinical Oncology membersClinical cancer careMost respondentsMedication optionsTobacco cessationCancer outcomesCancer careClinical OncologyPatientsPatient resistanceCancerOnline surveyCessationInterventionAdequate training